Similar effects were described by Britain et al. in the OV4 ovarian cancer cell line and confirmed that the sialylation of EGFR correlates with ST6Gal-I expression and protects against gefitinib-mediated apoptosis [126]. Here, ST6GAL1 is linked to ovarian carcinoma.